Susceptibility‐Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial
MicrobiologyOpen · 2026-06 · 15 (3)
DOI: 10.1002/mbo3.70313 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift MicrobiologyOpen, online erschienen am 17.05.2026. Verfasst von Kemei Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liaocheng People's Hospital, Liaocheng, Shandong Province, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents, Clarithromycin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Clarithromycin resistance is a major determinant of treatment failure, and the benefits of susceptibility‐guided therapy in high‐resistance settings remains incompletely understood. To evaluate the clinical effectiveness of the susceptibility‐guided compared with the empirical therapy in treatment‐naïve H. pylori infection in a high resistance setting. In this single‐centre, randomised, superiority trial, 500 treatment‐naïve adults were allocated (1:1) to susceptibility‐guided sequential therapy (SGT) or empirical clarithromycin ‐containing quadruple therapy (ET). Clarithromycin and levofloxacin antimicrobial resistance were determined using PCR. The primary endpoint was first‐line eradication in the intention‐to‐treat (ITT) population. Sensitivity analyses were performed using complete‐case and multiple imputation approaches. Among the 494 analysed participants (244 SGT, 250 ET), resistance to clarithromycin and levofloxacin was 69.3% and 51.6%, respectively. In the ITT analysis, first‐line eradication was achieved in 59.8% of participants in the SGT group and 62.8% in the ET group [absolute risk difference −3.0%; odds ratio (OR) = 0.882, 95% confidence interval (CI, 0.614–1.268), p = 0.499]. Per‐protocol eradication rates were 84.4% and 89.7%, respectively [absolute risk difference −5.3%; OR = 0.620, 95% CI (0.328–1.173), p = 0.139]. Notably, despite a clarithromycin resistance rate approaching 70%, empirical clarithromycin‐containing quadruple therapy achieved a high per‐protocol eradication rate. Sensitivity analyses yielded consistent results. In a high resistance region, PCR‐based susceptibility‐guided sequential therapy did not demonstrate superiority over empirical treatment. However, empirical clarithromycin ‐containing quadruple therapy maintained satisfactory efficacy. Overall, these findings have implications for treatment strategy selection in high‐resistance microbiological settings. Trial Registration: ClinicalTrials. gov Identifier: NCT05549115
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Liaocheng People's Hospital, Liaocheng, Shandong Province, China.
- Department of Gastroenterology, Shandong Province Maternal and Child Health Care Hospital, Jinan, Shandong Province, China.
- Department of Gastroenterology, Central Hospital affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
ORCID-Profile: Qian Feng, Lifeng Liu
Zitieren
APA
Lu, K., Zou, X., Lang, C., Zang, L., Yang, X., Sang, W., Wang, J., Feng, Q., Mu, Y., Liu, L., Xu, C., & Zhao, J. (2026). Susceptibility‐Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial. MicrobiologyOpen, 15(3). https://doi.org/10.1002/mbo3.70313
Vancouver
Lu K, Zou X, Lang C, Zang L, Yang X, Sang W, et al. Susceptibility‐Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial. MicrobiologyOpen. 2026;15(3). doi:10.1002/mbo3.70313
BibTeX
@article{Lu2026,
author = {Lu, Kemei and Zou, Xuefei and Lang, Cuicui and Zang, Lina and Yang, Xuechao and Sang, Weiwei and Wang, Jinyan and Feng, Qian and Mu, Ying and Liu, Lifeng and Xu, Chunhong and Zhao, Jingrun},
title = {Susceptibility‐Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial},
journal = {MicrobiologyOpen},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/mbo3.70313}
}
EUVIMED